Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma

F. Grosso, P. Dileo, R. Sanfilippo, S. Stacchiotti, R. Bertulli, C. Piovesan, J. Jimeno, M. D'Incalci, A. Gescher, P. G. Casali

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Trabectedin is a marine-derived cytoxic alkaloid which has shown promising antitumour activity in a variety of human malignancies including sarcoma. Fifty-four patients with advanced sarcoma (age 43 yrs, range 18-70), all pretreated with prior chemotherapy, were enrolled on a named individual basis for treatment with trabectedin. Diagnosis was adult soft tissue sarcoma (STS) in 46 patients, Ewing's family tumour (EFT) in 4, and osteosarcoma (OS) in 4. The initial 23 patients (total number of courses administered: 68) did not receive premedication prior to trabectedin, while the other 31 patients (total number of courses administered: 134) received premedication with dexamethasone 4 mg po bid 24 hours before therapy. Incidence of toxicity (grade 3-4), expressed as percentage of courses, was as follows: in patients without dexamethasone, elevation of transaminases 34%, neutropenia 24% and thrombocytopenia 25%; in patients with prior dexamethasone, elevation of transaminases 2%, neutropenia 2% and no thrombocytopenia. The median received dose intensity of trabectedin was superimposable in the two groups (404 μg and 400 μg per week, respectively), as well as progression-free survival (19% at 6 months). Among STS patients, 9% had objective responses. In this unselected patient series, premedication with dexamethasone strongly reduced drug-induced hepatotoxicity and myelosuppression.

Original languageEnglish
Pages (from-to)1484-1490
Number of pages7
JournalEuropean Journal of Cancer
Volume42
Issue number10
DOIs
Publication statusPublished - Jul 2006

Fingerprint

trabectedin
Premedication
Sarcoma
Bone Marrow
Steroids
Liver
Dexamethasone
Transaminases
Neutropenia
Ewing's Sarcoma
Osteosarcoma
Alkaloids

Keywords

  • Advanced sarcoma
  • Steroid premedication
  • Toxicity
  • Trabectedin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. / Grosso, F.; Dileo, P.; Sanfilippo, R.; Stacchiotti, S.; Bertulli, R.; Piovesan, C.; Jimeno, J.; D'Incalci, M.; Gescher, A.; Casali, P. G.

In: European Journal of Cancer, Vol. 42, No. 10, 07.2006, p. 1484-1490.

Research output: Contribution to journalArticle

@article{50968fa6d7184c0db85fd02c29c8fdae,
title = "Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma",
abstract = "Trabectedin is a marine-derived cytoxic alkaloid which has shown promising antitumour activity in a variety of human malignancies including sarcoma. Fifty-four patients with advanced sarcoma (age 43 yrs, range 18-70), all pretreated with prior chemotherapy, were enrolled on a named individual basis for treatment with trabectedin. Diagnosis was adult soft tissue sarcoma (STS) in 46 patients, Ewing's family tumour (EFT) in 4, and osteosarcoma (OS) in 4. The initial 23 patients (total number of courses administered: 68) did not receive premedication prior to trabectedin, while the other 31 patients (total number of courses administered: 134) received premedication with dexamethasone 4 mg po bid 24 hours before therapy. Incidence of toxicity (grade 3-4), expressed as percentage of courses, was as follows: in patients without dexamethasone, elevation of transaminases 34{\%}, neutropenia 24{\%} and thrombocytopenia 25{\%}; in patients with prior dexamethasone, elevation of transaminases 2{\%}, neutropenia 2{\%} and no thrombocytopenia. The median received dose intensity of trabectedin was superimposable in the two groups (404 μg and 400 μg per week, respectively), as well as progression-free survival (19{\%} at 6 months). Among STS patients, 9{\%} had objective responses. In this unselected patient series, premedication with dexamethasone strongly reduced drug-induced hepatotoxicity and myelosuppression.",
keywords = "Advanced sarcoma, Steroid premedication, Toxicity, Trabectedin",
author = "F. Grosso and P. Dileo and R. Sanfilippo and S. Stacchiotti and R. Bertulli and C. Piovesan and J. Jimeno and M. D'Incalci and A. Gescher and Casali, {P. G.}",
year = "2006",
month = "7",
doi = "10.1016/j.ejca.2006.02.010",
language = "English",
volume = "42",
pages = "1484--1490",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma

AU - Grosso, F.

AU - Dileo, P.

AU - Sanfilippo, R.

AU - Stacchiotti, S.

AU - Bertulli, R.

AU - Piovesan, C.

AU - Jimeno, J.

AU - D'Incalci, M.

AU - Gescher, A.

AU - Casali, P. G.

PY - 2006/7

Y1 - 2006/7

N2 - Trabectedin is a marine-derived cytoxic alkaloid which has shown promising antitumour activity in a variety of human malignancies including sarcoma. Fifty-four patients with advanced sarcoma (age 43 yrs, range 18-70), all pretreated with prior chemotherapy, were enrolled on a named individual basis for treatment with trabectedin. Diagnosis was adult soft tissue sarcoma (STS) in 46 patients, Ewing's family tumour (EFT) in 4, and osteosarcoma (OS) in 4. The initial 23 patients (total number of courses administered: 68) did not receive premedication prior to trabectedin, while the other 31 patients (total number of courses administered: 134) received premedication with dexamethasone 4 mg po bid 24 hours before therapy. Incidence of toxicity (grade 3-4), expressed as percentage of courses, was as follows: in patients without dexamethasone, elevation of transaminases 34%, neutropenia 24% and thrombocytopenia 25%; in patients with prior dexamethasone, elevation of transaminases 2%, neutropenia 2% and no thrombocytopenia. The median received dose intensity of trabectedin was superimposable in the two groups (404 μg and 400 μg per week, respectively), as well as progression-free survival (19% at 6 months). Among STS patients, 9% had objective responses. In this unselected patient series, premedication with dexamethasone strongly reduced drug-induced hepatotoxicity and myelosuppression.

AB - Trabectedin is a marine-derived cytoxic alkaloid which has shown promising antitumour activity in a variety of human malignancies including sarcoma. Fifty-four patients with advanced sarcoma (age 43 yrs, range 18-70), all pretreated with prior chemotherapy, were enrolled on a named individual basis for treatment with trabectedin. Diagnosis was adult soft tissue sarcoma (STS) in 46 patients, Ewing's family tumour (EFT) in 4, and osteosarcoma (OS) in 4. The initial 23 patients (total number of courses administered: 68) did not receive premedication prior to trabectedin, while the other 31 patients (total number of courses administered: 134) received premedication with dexamethasone 4 mg po bid 24 hours before therapy. Incidence of toxicity (grade 3-4), expressed as percentage of courses, was as follows: in patients without dexamethasone, elevation of transaminases 34%, neutropenia 24% and thrombocytopenia 25%; in patients with prior dexamethasone, elevation of transaminases 2%, neutropenia 2% and no thrombocytopenia. The median received dose intensity of trabectedin was superimposable in the two groups (404 μg and 400 μg per week, respectively), as well as progression-free survival (19% at 6 months). Among STS patients, 9% had objective responses. In this unselected patient series, premedication with dexamethasone strongly reduced drug-induced hepatotoxicity and myelosuppression.

KW - Advanced sarcoma

KW - Steroid premedication

KW - Toxicity

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=33745161449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745161449&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.02.010

DO - 10.1016/j.ejca.2006.02.010

M3 - Article

C2 - 16737808

AN - SCOPUS:33745161449

VL - 42

SP - 1484

EP - 1490

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -